Quick Answer
CalciMedica, Inc. reported R&D Expense of $15.23 million for fiscal year 2025.
CalciMedica, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $15.23M | +5.2% |
| 2024 | $14.48M | -8.7% |
| 2023 | $15.86M | +89.9% |
| 2022 | $8.35M | -55.8% |
| 2021 | $18.90M | -9.8% |
| 2020 | $20.96M | -31.5% |
| 2019 | $30.58M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.85M | +8.6% | -5.0% |
| June 30, 2025 | $4.05M | -2.5% | -4.1% |
| March 31, 2025 | $4.22M | +43.5% | +19.1% |
| September 30, 2024 | $3.55M | +27.9% | -14.7% |
| June 30, 2024 | $4.16M | +9.0% | +41.2% |
| March 31, 2024 | $2.94M | -54.6% | +6.2% |
| September 30, 2023 | $2.77M | +122.8% | -27.3% |
| June 30, 2023 | $3.81M | +68.8% | -41.2% |
- CalciMedica, Inc. showed an increase of +5.2% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, CalciMedica, Inc.’s r&d expense has declined by 50.2% (from $30.58 million to $15.23 million).
- The most recent figure is from CalciMedica, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: